(VIANEWS) – The NASDAQ opens in less than one hour and FibroGen‘s pre-market value is already 7.6% up.
FibroGen’s last close was $1.71, 91.82% under its 52-week high of $20.90.
The last session, NASDAQ finished with FibroGen (FGEN) dropping 5% to $1.71. NASDAQ slid 0.41% to $16,019.27, after two consecutive sessions in a row of losses, on what was a somewhat negative trend trading session.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-2.92.
Volume
Today’s last reported volume for FibroGen is 488146 which is 82.15% below its average volume of 2735720.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 49.4% and 55.6%, respectively.
Yearly Top and Bottom Value
FibroGen’s stock is valued at $1.71 at 09:24 EST, way under its 52-week high of $20.90 and way higher than its 52-week low of $0.33.
More news about FibroGen (FGEN).
